GENE ONLINE|News &
Opinion
Blog

2022-09-19| Trials & Approvals

AstraZeneca, Sanofi’s RSV Antibody Recommended For Approval In EU

by Joy Lin
Share To

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been recommended for EU approval by CHMP for the prevention of respiratory syncytial virus (RSV) infection in infants. The recommendation is based on results from three clinical trials of Beyfortus, which demonstrated protection against the disease during the RSV season with a single dose. 

If approved, Beyfortus will be the first and only single-dose passive immunization for the general infant population. 

Related article: A Cure for HIV Could Be Here Sooner Than You Think – Future of Health

Protection Against A Common Disease

RSV is the most common cause of lower respiratory tract infections (LRTIs) and a leading cause of hospitalization in infants. The disease was estimated to cost the global healthcare system €4.82 billion ($4.81 billion) in 2017. 

The current standard of care for RSV prophylaxis is Synagis (palivizumab), which was approved in 1998. Synagis is indicated for high-risk infants and is given several times over the RSV season. 

Beyfortus is designed to be administered via a single intramuscular injection which would confer protection against RSV during the viral season. 

The positive opinion by CHMP was based on results from the Beyfortus clinical development program, which includes the Melody Phase 3, Medley Phase 2/3, and Phase 2b trials. 

In Melody and Phase 2b trials, Beyfortus reduced the incidence of LRTIs caused by RSV compared to the placebo in a single dose. No clinically meaningful differences in safety results between the Beyfortus and placebo groups were seen. Beyfortus also showed a comparable safety and tolerability profile to Synagis (palivizumab) in the Medley 2/3.    

Beyfortus has been granted Breakthrough Therapy Designation in China and the US. The antibody is also included in EMA’s PRIME scheme and labeled a priority medicine in Japan. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Next-Generation Vaccines Advance Through Abu Dhabi DoH and Sanofi’s MoU Agreement at US BIO 2025
2025-06-26
Dupixent Makes History with FDA Approval as First New CSU Treatment in Over a Decade
2025-04-20
Astrazeneca’s Calquence Combination Recommended for EU Approval in Untreated MCL Patients
2025-04-04
LATEST
Arkansas Bans Pharmacy Benefit Managers from Owning Pharmacies
2025-07-14
Air Pollution, Inequality, and Weak Democracies Linked to Faster Aging in Global Study
2025-07-14
Analysis Reveals Publication Bias in Scientific Research Dates Back to Modern Science’s Origins
2025-07-14
Oncology Pharmacists Tackle Biosimilar Integration and 505(b)(2) Drug Adoption at ATOPP 2025 Conference
2025-07-14
Pneumococcal Vaccination Linked to Lower Risk of Severe COVID-19 Outcomes in Patients with Inflammatory Rheumatic Diseases
2025-07-14
Telepharmacy and Mobile Units Address Medication Access in Pharmacy Deserts
2025-07-14
Board-Certified Psychiatric Pharmacists Address Behavioral Health Workforce Shortages with Expertise in Psychopharmacology
2025-07-14
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top